NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client
January 16, 2024 08:30 ET
|
NightHawk Biosciences
DURHAM, N.C., Jan. 16, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO
January 08, 2024 08:30 ET
|
NightHawk Biosciences
DURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK; NHWK), an integrated contract development and manufacturing organization (CDMO), today announced that it...
NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
January 03, 2024 08:30 ET
|
NightHawk Biosciences
DURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
December 21, 2023 08:30 ET
|
NightHawk Biosciences
Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as...
NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company
December 18, 2023 08:30 ET
|
NightHawk Biosciences
Manufacturing run at Scorpius’ state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing Advances multi-million dollar biomanufacturing contract awarded earlier this...
NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets
December 12, 2023 08:30 ET
|
NightHawk Biosciences
Over $20 million in signed manufacturing contracts which includepremier biotech/pharma companies and research institutes Elusys divestiture and R&D cuts expected to eliminate over $40 million...
NightHawk Biosciences Provides Q3 2023 Business Update
November 20, 2023 16:05 ET
|
NightHawk Biosciences
DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
Teleradiology Service Market Size Projected to Reach US$ 22,069.5 Million with 12.20% CAGR Growth by 2033 | Future Market Insights, Inc.
October 30, 2023 11:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The teleradiology service market is projected to surpass US$ 6,980.1 million in 2023 and is likely to attain a valuation of US$ 22,069.5 million by...
The Global Captive Portal Market size is expected to reach $2.3 billion by 2030, rising at a market growth of 13.8% CAGR during the forecast period
August 30, 2023 11:09 ET
|
ReportLinker
New York, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Captive Portal Market Size, Share & Industry Trends Analysis Report By Offering, By...
NightHawk Biosciences Provides Q2 2023 Business Update
August 14, 2023 16:05 ET
|
NightHawk Biosciences
DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...